Literature DB >> 26514749

Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure.

Mohammed Siddiqui1, Tanja Dudenbostel1, David A Calhoun2.   

Abstract

Resistant or difficult to treat hypertension is defined as high blood pressure that remains uncontrolled with 3 or more different antihypertensive medications, including a diuretic. Recent definitions also include controlled blood pressure with use of 4 or more medications as also being resistant to treatment. Recently, refractory hypertension, an extreme phenotype of antihypertensive treatment failure has been defined as hypertension uncontrolled with use of 5 or more antihypertensive agents, including a long-acting thiazide diuretic and a mineralocorticoid receptor antagonist. Patients with resistant vs refractory hypertension share similar characteristics and comorbidities, including obesity, African American race, female sex, diabetes, coronary heart disease, chronic kidney disease, and obstructive sleep apnea. Patients with refractory vs resistant hypertension tend to be younger and are more likely to have been diagnosed with congestive heart failure. Refractory hypertension might also differ from resistant hypertension in terms of underlying cause. Preliminary evidence suggests that refractory hypertension is more likely to be neurogenic in etiology (ie, heightened sympathetic tone), vs a volume-dependent hypertension that is more characteristic of resistant hypertension in general.
Copyright © 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26514749      PMCID: PMC5636623          DOI: 10.1016/j.cjca.2015.06.033

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  14 in total

1.  Hyperaldosteronism among black and white subjects with resistant hypertension.

Authors:  David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Roopal B Thakkar; Paula Weissmann
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

2.  Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

Authors:  William C Cushman; Charles E Ford; Jeffrey A Cutler; Karen L Margolis; Barry R Davis; Richard H Grimm; Henry R Black; Bruce P Hamilton; Joanne Holland; Chuke Nwachuku; Vasilios Papademetriou; Jeffery Probstfield; Jackson T Wright; Michael H Alderman; Robert J Weiss; Linda Piller; Judy Bettencourt; Sandra M Walsh
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738

Review 3.  Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?

Authors:  Nitin Khosla; Dave Y Chua; William J Elliott; George L Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-06       Impact factor: 3.738

4.  Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.

Authors:  Michael E Ernst; Barry L Carter; Chris J Goerdt; Jennifer J G Steffensmeier; Beth Bryles Phillips; M Bridget Zimmerman; George R Bergus
Journal:  Hypertension       Date:  2006-01-23       Impact factor: 10.190

5.  Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study.

Authors:  J Redon; C Campos; M L Narciso; J L Rodicio; J M Pascual; L M Ruilope
Journal:  Hypertension       Date:  1998-02       Impact factor: 10.190

6.  Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort.

Authors:  David A Calhoun; John N Booth; Suzanne Oparil; Marguerite R Irvin; Daichi Shimbo; Daniel T Lackland; George Howard; Monika M Safford; Paul Muntner
Journal:  Hypertension       Date:  2013-12-09       Impact factor: 10.190

7.  Efficacy of low-dose spironolactone in subjects with resistant hypertension.

Authors:  Mari Konishi Nishizaka; Mohammad Amin Zaman; David A Calhoun
Journal:  Am J Hypertens       Date:  2003-11       Impact factor: 2.689

8.  Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion.

Authors:  Krishna K Gaddam; Mari K Nishizaka; Monique N Pratt-Ubunama; Eduardo Pimenta; Inmaculada Aban; Suzanne Oparil; David A Calhoun
Journal:  Arch Intern Med       Date:  2008-06-09

9.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

10.  Refractory hypertension: definition, prevalence, and patient characteristics.

Authors:  Maria Czarina Acelajado; Roberto Pisoni; Tanja Dudenbostel; Louis J Dell'Italia; Falynn Cartmill; Bin Zhang; Stacey S Cofield; Suzanne Oparil; David A Calhoun
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-11-15       Impact factor: 3.738

View more
  17 in total

1.  Morning Diastolic Blood Pressure May Be Independently Associated With Severity of Obstructive Sleep Apnea in Non-Hypertensive Patients: A Cross-Sectional Study.

Authors:  Łukasz Mokros; Wojciech Kuczyński; Łukasz Franczak; Piotr Białasiewicz
Journal:  J Clin Sleep Med       Date:  2017-07-15       Impact factor: 4.062

2.  Hypertension-Linked Pathophysiological Alterations in the Gut.

Authors:  Monica M Santisteban; Yanfei Qi; Jasenka Zubcevic; Seungbum Kim; Tao Yang; Vinayak Shenoy; Colleen T Cole-Jeffrey; Gilberto O Lobaton; Daniel C Stewart; Andres Rubiano; Chelsey S Simmons; Fernando Garcia-Pereira; Richard D Johnson; Carl J Pepine; Mohan K Raizada
Journal:  Circ Res       Date:  2016-10-31       Impact factor: 17.367

3.  Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting.

Authors:  Oyunbileg Magvanjav; Rhonda M Cooper-Dehoff; Caitrin W McDonough; Yan Gong; William R Hogan; Julie A Johnson
Journal:  Am J Hypertens       Date:  2020-04-01       Impact factor: 2.689

Review 4.  Pathophysiology and Potential Non-Pharmacologic Treatments of Obesity or Kidney Disease Associated Refractory Hypertension.

Authors:  Thierry H Le Jemtel; William Richardson; Rohan Samson; Abhishek Jaiswal; Suzanne Oparil
Journal:  Curr Hypertens Rep       Date:  2017-02       Impact factor: 5.369

Review 5.  Resistant Hypertension: Mechanisms and Treatment.

Authors:  Andrew Y Hwang; Eric Dietrich; Carl J Pepine; Steven M Smith
Journal:  Curr Hypertens Rep       Date:  2017-07       Impact factor: 5.369

Review 6.  Changing concepts in hypertension management.

Authors:  P S Gudsoorkar; S W Tobe
Journal:  J Hum Hypertens       Date:  2017-07-27       Impact factor: 3.012

7.  Selective Deletion of the Brain-Specific Isoform of Renin Causes Neurogenic Hypertension.

Authors:  Keisuke Shinohara; Xuebo Liu; Donald A Morgan; Deborah R Davis; Maria Luisa S Sequeira-Lopez; Martin D Cassell; Justin L Grobe; Kamal Rahmouni; Curt D Sigmund
Journal:  Hypertension       Date:  2016-10-17       Impact factor: 10.190

Review 8.  Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure.

Authors:  Tanja Dudenbostel; Mohammed Siddiqui; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2016-04-18       Impact factor: 10.190

Review 9.  Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

10.  Self-blood pressure monitoring is associated with improved awareness, adherence, and attainment of target blood pressure goals: Prospective observational study of 7751 patients.

Authors:  Sang-Ho Jo; Sung-Ai Kim; Kyoung-Ha Park; Hyun-Sook Kim; Sang-Jin Han; Woo-Jung Park
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-08-08       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.